Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
11/2002
11/28/2002US20020178135 Image searching system and image searching method, and a recording medium storing an image searching program
11/28/2002US20020177618 ERK (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
11/28/2002US20020177609 Fatty alcohol drug conjugates
11/28/2002US20020177601 Inhibit the signal transduction by tyrosine kinases; e.g. 4-(3-chloro-4-fluorophenylamino)-6-(3-(4-(methoxycarbonyl-methyl)-1 -piperazinyl)propyloxy)-7-methoxyquinazoline; use such as antitumor agent
11/28/2002US20020177587 Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP)
11/28/2002US20020177586 Method for treating fibrotic diseases or other indications ID
11/28/2002US20020177545 Compositions and methods for treating gonadotrophin related illnesses
11/28/2002US20020177213 Tissue plasminogen activator-like protease
11/28/2002US20020176888 Oral dosage forms
11/28/2002DE10125763A1 New use of indirubin derivatives as VEGF inhibitors useful for preparing medicaments useful for e.g. treating cancer, autoimmune diseases, cardiovascular diseases or viral infections
11/28/2002DE10125145A1 New C-furanyl- or C-thienyl-methylamine derivatives, useful e.g. for treating arrhythmia, emesis, inflammation, cardiovascular or neurodegenerative disease, asthma, glaucoma or especially pain
11/28/2002DE10123586A1 New 3,5-diamino-1,2,4-triazole derivatives, are cyclin dependent kinase inhibitors useful for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
11/28/2002CA2448449A1 Treatment of renal fibrosis
11/28/2002CA2447671A1 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
11/28/2002CA2447598A1 Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
11/28/2002CA2447233A1 Process for the production of quinazolines
11/28/2002CA2447103A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002CA2447020A1 The use of 4-aminopyridine derivatives for the treatment of mglur5 receptor mediated diseases
11/28/2002CA2446734A1 Antibodies against tumor necrosis factor delta (april)
11/28/2002CA2446331A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002CA2446313A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002CA2445631A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002CA2445010A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
11/28/2002CA2441801A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/27/2002EP1260587A2 Tyrosyl tRNA synthetase
11/27/2002EP1260519A1 Membrane receptors for steroids and sterols
11/27/2002EP1259612A2 G-protein coupled receptor related polypeptides
11/27/2002EP1259527A1 35 human secreted proteins
11/27/2002EP1259514A2 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
11/27/2002EP1259510A2 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
11/27/2002EP1259505A2 Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
11/27/2002EP1259504A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents
11/27/2002EP1259491A1 4-imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates and amides and their use as alpha-1a agonists
11/27/2002EP1259488A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors
11/27/2002EP1259481A1 Substituted benzoylguanidines, method for their production, their use as a medicament or diagnostic agent and a medicament containing the same
11/27/2002EP1259477A1 Aminoadamantane derivatives as therapeutic agents
11/27/2002EP1259243A2 Bupropion metabolites and methods of their synthesis and use
11/27/2002EP1259242A2 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
11/27/2002EP1017672B1 New npy antagonists
11/27/2002EP1000048B1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives
11/27/2002EP1000035B1 Substituted 6-phenylphenanthridines
11/27/2002EP0585267B1 Herpesvirus particle preparation and vaccine
11/27/2002CN1382154A Basic monocyclic compounds having NK2 antagonist action processes for their preparation and formulations containing them
11/27/2002CN1382144A Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
11/27/2002CN1382136A N-heterocyclic derivatives as NOS inhibitors
11/27/2002CN1382125A Bicycle vasporession agonists
11/27/2002CN1382124A Bicycle androgen and progesterone receptor modulator compounds and methods
11/27/2002CN1382121A C16 unsaturated FP-selective prostaglandins analogs
11/27/2002CN1382119A Substituted alpha hydroxy acid aspertate specific cysteine protease inhibitors and use thereof
11/27/2002CN1382052A Use of dipyridazole or mopidamol in the manufacture of a medicament for treatment and prevention of fibrin-dependent microcirculation disorders
11/27/2002CN1381256A Composite Chinese medicine for treating prostatitis
11/26/2002US6486322 Azaindole derivatives, process for their preparation, and their use as antitumor agents
11/26/2002US6486305 Method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3
11/26/2002US6486186 Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same
11/26/2002US6485960 Polycystic kidney disease 1 gene and uses thereof
11/26/2002US6485755 Methods of using electron active compounds for managing cancer
11/26/2002US6485745 Dosage form exhibits accelerated release of the active agent
11/26/2002US6485704 Azo compound for type I pototherapy
11/26/2002CA2258285C Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
11/22/2002WO2001090079A2 Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists
11/22/2002CA2410304A1 Novel carbamates and ureas production and use thereof as endothelin receptor antagonists
11/21/2002WO2002092841A2 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
11/21/2002WO2002092808A1 Random gene unidirectional antisense library
11/21/2002WO2002092807A1 Unigene unidirectional antisense library
11/21/2002WO2002092781A2 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002WO2002092759A2 Molecules for disease detection and treatment
11/21/2002WO2002092629A1 Polynucleotides and polypeptides linked to cancer and/or tumorigenesis
11/21/2002WO2002092593A1 4-(4-pyridazinyl)pyrazole derivatives
11/21/2002WO2002092588A2 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002WO2002092576A1 Diarylurea derivatives useful as anti-inflammatory agents
11/21/2002WO2002092573A2 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
11/21/2002WO2002092568A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors
11/21/2002WO2002092567A1 Novel 5-phenyl-1h-indole derivatives as antagonists of interleukine-8 receptors
11/21/2002WO2002092565A2 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
11/21/2002WO2002092553A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002WO2002092129A2 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist
11/21/2002WO2002092111A1 Use of extracts and preparations from iris plants and tectorigenin as medicaments
11/21/2002WO2002092089A1 Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002WO2002092087A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002WO2002092079A1 Utilization of selective indirubin derivatives as vegf-r inhibitors
11/21/2002WO2002092068A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient
11/21/2002WO2002092004A2 Use of hmg fragment as anti-inflammatory agents
11/21/2002WO2002091993A2 Estrogen receptor modulators
11/21/2002WO2002091833A1 Prebiotic and probiotic compositions and methods for their use in gut-based therapies
11/21/2002WO2002081728A3 Quinoline inhibitors of hyak1 and hyak3 kinases
11/21/2002WO2002062343A3 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/21/2002WO2002055514A3 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators
11/21/2002WO2002053528A8 Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
11/21/2002WO2002049649A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
11/21/2002WO2002018341A9 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors
11/21/2002US20020173661 Phosphodiesterase-4 (PDE4); thiazole-containing pyridine (N-oxide) compounds; 4-(2-(3,4-Bis(difluoromethoxy)phenyl)-2-(5-(2-(1-hydroxy-1 -methyl)ethyl)thiazolyl)ethyl)pyridine N-oxide for example
11/21/2002US20020173646 Quinazoline derivatives and pharmaceutical compositions containing them
11/21/2002US20020173514 Pyridine-substituted pyrazolopyridine derivatives
11/21/2002US20020173507 Antiproliferative agents; apoptosis; anticancer agents
11/21/2002US20020173500 Hypotensive agents; antiischemic agents
11/21/2002US20020173499 Estrogen replacement therapy
11/21/2002US20020173460 Complexing with fibronectins; analyzing, calibration; antiinflammatory agents, respiratory system disorders
11/21/2002US20020173453 Administering mammals a bone morphogenic protein, transforming growth factor, fibroblast growth factor
11/21/2002US20020173445 Selective androgen receptor modulators and methods for their identification, design and use
11/21/2002US20020172674 Administering formulation selected from a BAFF-R polypeptide or fragment; a chimeric molecule comprising a BAFF-R polypeptide or fragment fused to heterologous amino acid sequence; anti-BAFF-R antibody for inhibiting B-cell growth
1 ... 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 ... 562